Article
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles.
European journal of preventive cardiology - 1 Mar 2017
Gregson John M, Freitag Daniel F, Surendran Praveen, Stitziel Nathan O, Chowdhury Rajiv, Burgess Stephen, Kaptoge Stephen, Gao Pei, Staley James R, Willeit Peter, Nielsen Sune F, Caslake Muriel, Trompet Stella, Polfus Linda M, Kuulasmaa Kari, Kontto Jukka, Perola Markus, Blankenberg Stefan, Veronesi Giovanni, Gianfagna Francesco, Männistö Satu, Kimura Akinori, Lin Honghuang, Reilly Dermot F, Gorski Mathias, Mijatovic Vladan, Munroe Patricia B, Ehret Georg B, Thompson Alex, Uria-Nickelsen Maria, Malarstig Anders, Dehghan Abbas, Vogt Thomas F, Sasaoka Taishi, Takeuchi Fumihiko, Kato Norihiro, Yamada Yoshiji, Kee Frank, Müller-Nurasyid Martina, Ferrières Jean, Arveiler Dominique, Amouyel Philippe, Salomaa Veikko, Boerwinkle Eric, Thompson Simon G, Ford Ian, Wouter Jukema J, Sattar Naveed, Packard Chris J, Shafi Majumder Abdulla Al, Alam Dewan S, Deloukas Panos, Schunkert Heribert, Samani Nilesh J, Kathiresan Sekar, Nordestgaard Børge G, Saleheen Danish, Howson Joanna Mm, Di Angelantonio Emanuele, Butterworth Adam S, Danesh John
Abstract excerpt
Aims Darapladib, a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), has not reduced risk of cardiovascular disease outcomes in recent randomized trials. We aimed to test whether Lp-PLA2 enzyme activity is causally relevant to coronary heart disease. Methods In 72,657 patients with coronary heart disease and 110,218 controls in 23 epidemiological studies, we genotyped five functional...
Read the complete abstract on PubMed